File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Acute lymphoblastic leukaemia (ALL) in Hong Kong children: treatment outcome from 1993 to 2012

TitleAcute lymphoblastic leukaemia (ALL) in Hong Kong children: treatment outcome from 1993 to 2012
Authors
KeywordsMedical sciences
Oncology medical sciences
Pediatrics
Issue Date2013
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/
Citation
The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 71, abstract no. P-0070 How to Cite?
AbstractPURPOSE/OBJECTIVE: To study demographic features of ALL and treatment outcome over past 20 years in Hong Kong. MATERIALS AND METHODS: HKPHOSG conducted 4 clinical trials on ALL since 1993, namely HKALL93, HKALL97, IC-BFM ALL 2002, and CCLG2008. Data were collected prospectively and follow-up of all recruited cases until Dec 2012. RESULTS: 624 patients were recruited into above studies and another 26 patients recruited into 3 international studies (EsPhALL and Interfant). Each trial ran for 58-64 months, CCLG 2008 study is still on-going. Number of subjects recruited were 152 (ALL93), 171 (HKALL97) and 175 (IC-BFM2002). There were no significant changes in demographic features including median age (4.9-5.6 years), presenting WBC (10.2-18.1), T cell (8-13%) at diagnosis. CNS leukaemia at presentation was 0.5-2%, and CNS 2 in recent 2 studies was 6%. Ph+ or BCR-ABL positive was 2.8%, E2A-PBX 4.3%, TEL-AML1 19.3%, hyperdiploidy 16%. Using NCI stratification, 59.5% patients belonged to standard risk. 91.4% had good prednisone response and CR rate 95.2-98.9%. Induction death was 2.2%, and similar over the 2 decades. Relapse rate decreased from 40.1% to 17.1%, death rate decreased from 26.3% to 12%, CNS relapse rate decreased from 5.5% to 0.8% despite reduction of cranial radiotherapy from 24.3% to 14.3%. 63 patients (10.1%) received allogeneic SCT, 20 patients received SCT in CR1. 5 year OS was 78.9%, 85.9% and 88.5%, EFS was 62.6%, 78.4% and 80% for HK93, 97 and 2002 studies respectively. 10 year OS was 76.2% and 82.9%, 10 year EFS was 56.3% and 76.9% for HK93 and 97 studies. 9 patients developed second malignancy. CONCLUSIONS: There was no change in demographic features of ALL in past 2 decades. Addition of delayed intensification improved EFS by 20%. Reduction of cranial RT did not increase CNS relapse when optimal systemic and intrathecal therapy administered. Acknowledgement: Children Cancer Foundation support for data manager.
DescriptionPoster Session - Acute Lymphoblastic Leukaemia: no. P-0070
This journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013
Persistent Identifierhttp://hdl.handle.net/10722/197711
ISSN
2015 Impact Factor: 2.634
2015 SCImago Journal Rankings: 1.505

 

DC FieldValueLanguage
dc.contributor.authorLi, CKen_US
dc.contributor.authorHa, SYen_US
dc.contributor.authorLee, Ven_US
dc.contributor.authorYuen, HLen_US
dc.contributor.authorLi, CHen_US
dc.contributor.authorLing, SCen_US
dc.contributor.authorShing, MMKen_US
dc.contributor.authorChan, GCFen_US
dc.contributor.authorLuk, CWen_US
dc.contributor.authorLee, ACWen_US
dc.contributor.authorCheuk, DKLen_US
dc.contributor.authorLeung, AWKen_US
dc.date.accessioned2014-05-29T08:45:05Z-
dc.date.available2014-05-29T08:45:05Z-
dc.date.issued2013en_US
dc.identifier.citationThe 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 71, abstract no. P-0070en_US
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/197711-
dc.descriptionPoster Session - Acute Lymphoblastic Leukaemia: no. P-0070-
dc.descriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013-
dc.description.abstractPURPOSE/OBJECTIVE: To study demographic features of ALL and treatment outcome over past 20 years in Hong Kong. MATERIALS AND METHODS: HKPHOSG conducted 4 clinical trials on ALL since 1993, namely HKALL93, HKALL97, IC-BFM ALL 2002, and CCLG2008. Data were collected prospectively and follow-up of all recruited cases until Dec 2012. RESULTS: 624 patients were recruited into above studies and another 26 patients recruited into 3 international studies (EsPhALL and Interfant). Each trial ran for 58-64 months, CCLG 2008 study is still on-going. Number of subjects recruited were 152 (ALL93), 171 (HKALL97) and 175 (IC-BFM2002). There were no significant changes in demographic features including median age (4.9-5.6 years), presenting WBC (10.2-18.1), T cell (8-13%) at diagnosis. CNS leukaemia at presentation was 0.5-2%, and CNS 2 in recent 2 studies was 6%. Ph+ or BCR-ABL positive was 2.8%, E2A-PBX 4.3%, TEL-AML1 19.3%, hyperdiploidy 16%. Using NCI stratification, 59.5% patients belonged to standard risk. 91.4% had good prednisone response and CR rate 95.2-98.9%. Induction death was 2.2%, and similar over the 2 decades. Relapse rate decreased from 40.1% to 17.1%, death rate decreased from 26.3% to 12%, CNS relapse rate decreased from 5.5% to 0.8% despite reduction of cranial radiotherapy from 24.3% to 14.3%. 63 patients (10.1%) received allogeneic SCT, 20 patients received SCT in CR1. 5 year OS was 78.9%, 85.9% and 88.5%, EFS was 62.6%, 78.4% and 80% for HK93, 97 and 2002 studies respectively. 10 year OS was 76.2% and 82.9%, 10 year EFS was 56.3% and 76.9% for HK93 and 97 studies. 9 patients developed second malignancy. CONCLUSIONS: There was no change in demographic features of ALL in past 2 decades. Addition of delayed intensification improved EFS by 20%. Reduction of cranial RT did not increase CNS relapse when optimal systemic and intrathecal therapy administered. Acknowledgement: Children Cancer Foundation support for data manager.-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/-
dc.relation.ispartofPediatric Blood & Canceren_US
dc.rightsPediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectPediatrics-
dc.titleAcute lymphoblastic leukaemia (ALL) in Hong Kong children: treatment outcome from 1993 to 2012en_US
dc.typeConference_Paperen_US
dc.identifier.emailHa, SY: syha@hku.hken_US
dc.identifier.emailChan, GCF: gcfchan@hku.hken_US
dc.identifier.emailCheuk, DKL: klcheuk@hkucc.hku.hk-
dc.identifier.doi10.1002/pbc.24719-
dc.identifier.hkuros229020en_US
dc.identifier.volume60-
dc.identifier.issueS3-
dc.identifier.spage71-
dc.identifier.epage71-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats